Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November...

Click to view original post